# CV Sciences, Inc. (CVSI)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/cv-sciences-inc/ JSON: https://steadybase.io/company/cv-sciences-inc.json Checked Nov 10, 2026. Latest filing read: Aug 13, 2026.

## Company

- Legal name: CV Sciences, Inc.
- Ticker: CVSI (OTC)
- SEC CIK: 0001510964
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: San Diego, CA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: cvsciences.com
- Investor relations: https://ir.cvsciences.com
- LinkedIn: https://www.linkedin.com/company/cv-sciences
- Next earnings date: Nov 12, 2026

## Key facts

- Revenue: $13.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526126598/0001193125-26-126598-index.html
- Operating income: -$470,000 for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526126598/0001193125-26-126598-index.html
- Net income: -$958,000 for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526126598/0001193125-26-126598-index.html
- SG&A: $7.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526126598/0001193125-26-126598-index.html
- Employees: 44 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526126598/cvsi-20251231.htm
- Shares outstanding: 225,829,128 as of Aug 11, 2026 (10-Q filed Aug 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526349211/0001193125-26-349211-index.html
- Auditor: Haskell & White LLP, Irvine, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526126598/cvsi-20251231.htm

## Business

CV Sciences, Inc. (“CV Sciences,” the “Company,” “we,” “our” or “us”) is a consumer wellness company specializing in nutraceuticals and plant-based foods. Our hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (“B2B”) to business-to-consumer (“B2C”).

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1510964/000119312526126598/cvsi-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $13.8M | -$470,000 | -$958,000 | $7.6M |
| Dec 31, 2024 | $15.7M | -$2.2M | -$2.4M | $9.2M |
| Dec 31, 2023 | $16.0M | $3.4M | $3.1M | $9.7M |
| Dec 31, 2022 | $16.2M | -$6.8M | -$8.2M | $12.1M |
| Dec 31, 2021 | $20.0M | -$18.4M | -$15.6M | $25.9M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/cv-sciences-inc.json

## Officers and directors

- Joseph D. Dowling, Chief Executive Officer and Director. LinkedIn: https://linkedin.com/in/jddowling. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1510964/000119312526126598/cvsi-20251231.htm
- Joerg Grasser, Chief Financial Officer. LinkedIn: https://linkedin.com/in/joerg-grasser-6791432ba. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1510964/000119312526126598/cvsi-20251231.htm

## Recent 8-K events

- Oct 26, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526432066/cvsi-20261023.htm
- Aug 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526349136/cvsi-20260813.htm
- Jun 4, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526257417/cvsi-20250602.htm
- May 14, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526223967/cvsi-20260514.htm
- Apr 10, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526151228/cvsi-20260406.htm
- Mar 26, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526126211/cvsi-20260326.htm
- Mar 10, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 3.02, Unregistered sales of equity securities; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312526100436/cvsi-20260304.htm
- Nov 13, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312525280116/cvsi-20251113.htm
- Oct 10, 2025: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312525237188/cvsi-20251007.htm
- Sep 18, 2025: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1510964/000119312525207436/cvsi-20250912.htm

## Latest filings

- 8-K filed Oct 26, 2026: https://www.sec.gov/Archives/edgar/data/1510964/000119312526432066/cvsi-20261023.htm
- 10-K filed Mar 26, 2026: https://www.sec.gov/Archives/edgar/data/1510964/000119312526126598/cvsi-20251231.htm
- 10-Q filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/1510964/000119312526349211/cvsi-20260630.htm
- DEF 14A filed Apr 15, 2026: https://www.sec.gov/Archives/edgar/data/1510964/000119312526155621/cvsi-20260415.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/